AG˹ٷ

STOCK TITAN

[S-8] SERVICENOW, INC. Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

ACM Research, Inc. (Ticker: ACMR) � Form 144 filing

An individual named Lisa Yi Lu Feng has filed a notice to sell up to 15,000 common shares of ACM Research, Inc. through Morgan Stanley Smith Barney LLC. The approximate sale date is 07 July 2025. Based on the filing, the shares are valued at an aggregate market price of $420,000, representing roughly 0.023 % of the 63,864,504 shares outstanding. The shares were acquired on the same day through a stock-option exercise paid in cash.

The filer also disclosed a prior sale of 15,000 shares on 24 June 2025 that generated $390,000 in gross proceeds.

  • No relationship to the issuer was specified in the form, and no adverse information was cited.
  • The filing indicates compliance with Rule 144 and possible 10b5-1 planning, but no plan adoption date is provided.

The transaction is small relative to ACMR’s share count, suggesting limited share-supply impact. However, repeated insider-level sales within a short window may draw investor attention.

ACM Research, Inc. (Ticker: ACMR) � Deposito Form 144

Una persona di nome Lisa Yi Lu Feng ha presentato una comunicazione per la vendita di un massimo di 15.000 azioni ordinarie di ACM Research, Inc. tramite Morgan Stanley Smith Barney LLC. La data approssimativa della vendita è il 7 luglio 2025. In base alla comunicazione, le azioni sono valutate complessivamente a 420.000 $, rappresentando circa lo 0,023% delle 63.864.504 azioni in circolazione. Le azioni sono state acquisite lo stesso giorno mediante un esercizio di opzioni azionarie pagato in contanti.

La dichiarante ha inoltre rivelato una vendita precedente di 15.000 azioni avvenuta il 24 giugno 2025, che ha generato 390.000 $ di ricavi lordi.

  • Nel modulo non è stata specificata alcuna relazione con l’emittente e non sono state citate informazioni negative.
  • Il deposito indica conformità alla Regola 144 e possibile pianificazione secondo la regola 10b5-1, ma non è stata fornita la data di adozione del piano.

La transazione è di entità ridotta rispetto al numero totale di azioni ACMR, suggerendo un impatto limitato sull’offerta di azioni. Tuttavia, vendite ripetute da parte di insider in un breve arco di tempo potrebbero attirare l’attenzione degli investitori.

ACM Research, Inc. (Ticker: ACMR) � Presentación del Formulario 144

Una persona llamada Lisa Yi Lu Feng ha presentado un aviso para vender hasta 15,000 acciones comunes de ACM Research, Inc. a través de Morgan Stanley Smith Barney LLC. La fecha aproximada de venta es el 7 de julio de 2025. Según la presentación, las acciones tienen un valor agregado de $420,000, lo que representa aproximadamente el 0,023 % de las 63,864,504 acciones en circulación. Las acciones fueron adquiridas ese mismo día mediante un ejercicio de opciones sobre acciones pagado en efectivo.

El declarante también reveló una venta previa de 15,000 acciones el 24 de junio de 2025 que generó $390,000 en ingresos brutos.

  • No se especificó ninguna relación con el emisor en el formulario, ni se mencionó información adversa.
  • La presentación indica cumplimiento con la Regla 144 y posible planificación 10b5-1, pero no se proporcionó la fecha de adopción del plan.

La transacción es pequeña en relación con el número de acciones de ACMR, lo que sugiere un impacto limitado en la oferta de acciones. Sin embargo, ventas repetidas a nivel de insider en un corto período pueden llamar la atención de los inversores.

ACM Research, Inc. (티커: ACMR) � Form 144 제출

Lisa Yi Lu Feng라는 개인� Morgan Stanley Smith Barney LLC� 통해 ACM Research, Inc.� 15,000 보통�까지 매도� 예정임을 신고했습니다. 예상 매도일은 2025� 7� 7�입니�. 제출서에 따르�, 해당 주식� � 시장 가치는 � 420,000 달러�, 전체 발행 주식 63,864,504주의 � 0.023%� 해당합니�. � 주식은 같은 � 주식 옵션 행사� 통해 현금으로 취득되었습니�.

신고자는 또한 2025� 6� 24�15,000�� 매도하여 � 390,000 달러� 매출� 올린 사실� 공개했습니다.

  • 서식에는 발행사와� 관계가 명시되지 않았으며, 부정적� 정보� 없었습니�.
  • 신고� Rule 144 준� � 10b5-1 계획 가능성� 나타내지�, 계획 채택 날짜� 제공되지 않았습니�.

이번 거래� ACMR� � 주식 수에 비해 적은 규모�, 주식 공급� 미치� 영향은 제한적일 것으� 보입니다. 다만, 짧은 기간 � 반복적인 내부� 매도� 투자자들� 관심을 � � 있습니다.

ACM Research, Inc. (Symbole : ACMR) � Dépôt du formulaire 144

Une personne nommée Lisa Yi Lu Feng a déposé un avis pour vendre jusqu’� 15 000 actions ordinaires d’ACM Research, Inc. via Morgan Stanley Smith Barney LLC. La date approximative de la vente est le 7 juillet 2025. Selon le dépôt, les actions sont évaluées à un prix de marché total d’environ 420 000 $, ce qui représente environ 0,023 % des 63 864 504 actions en circulation. Les actions ont été acquises le même jour par l’exercice d�options d’achat d’actions payées en espèces.

Le déclarant a également révélé une vente antérieure de 15 000 actions le 24 juin 2025, générant 390 000 $ de produit brut.

  • Aucune relation avec l’émetteur n’a été spécifiée dans le formulaire, et aucune information défavorable n’a été mentionnée.
  • Le dépôt indique une conformité à la règle 144 et une planification possible selon la règle 10b5-1, mais aucune date d’adoption du plan n’est fournie.

La transaction est faible par rapport au nombre d’actions ACMR, suggérant un impact limité sur l’offre d’actions. Toutefois, des ventes répétées par des initiés sur une courte période pourraient attirer l’attention des investisseurs.

ACM Research, Inc. (Ticker: ACMR) � Form 144 Einreichung

Eine Person namens Lisa Yi Lu Feng hat eine Mitteilung eingereicht, um bis zu 15.000 Stammaktien von ACM Research, Inc. über Morgan Stanley Smith Barney LLC zu verkaufen. Das ungefähre Verkaufsdatum ist der 7. Juli 2025. Laut Einreichung haben die Aktien einen Gesamtmarktwert von 420.000 $ und entsprechen etwa 0,023 % der 63.864.504 ausstehenden Aktien. Die Aktien wurden am selben Tag durch die Ausübung von Aktienoptionen gegen Barzahlung erworben.

Der Einreicher gab außerdem einen vorherigen Verkauf von 15.000 Aktien am 24. Juni 2025 bekannt, der einen Bruttoerlös von 390.000 $ erzielte.

  • Im Formular wurde keine Beziehung zum Emittenten angegeben und keine negativen Informationen genannt.
  • Die Einreichung weist auf die Einhaltung von Regel 144 und mögliche 10b5-1-Planung hin, jedoch wurde kein Planannahmedatum angegeben.

Die Transaktion ist im Verhältnis zur Aktienanzahl von ACMR gering und dürfte die Aktienversorgung nur begrenzt beeinflussen. Wiederholte Insider-Verkäufe innerhalb kurzer Zeit könnten jedoch die Aufmerksamkeit der Investoren auf sich ziehen.

Positive
  • Transparent Rule 144 compliance ensures public notice of insider-level share disposition.
  • Low relative size (0.023 % of shares outstanding) limits market-impact risk.
Negative
  • Repeat insider-level sales within a short period could be perceived negatively by some investors.
  • No relationship disclosure leaves uncertainty about the seller’s role and potential informational advantage.

Insights

TL;DR: Small Rule 144 sale (15k shares, $420k) � neutral impact given <0.1 % float.

The proposed sale equals just 0.023 % of shares outstanding, implying de-minimis dilution or supply effect. Rule 144 filings are routine and signal planned liquidity rather than directional insight. The same seller disposed of an identical amount two weeks earlier, which could indicate personal diversification. No relationship or executive title is listed, so the informational value for forecasting insider sentiment is limited. Overall, I view the filing as not materially impactful to ACMR’s valuation or float dynamics.

TL;DR: Routine compliance disclosure; repeated sales may raise modest governance watch-points.

Rule 144 ensures transparency around restricted-share resales. The filer certifies absence of undisclosed adverse information, meeting governance norms. Yet, two identical sales within three weeks may prompt monitoring for additional planned disposals, especially if the seller holds an influential role that is not clarified here. Lack of 10b5-1 adoption date slightly weakens best-practice optics but does not breach regulation. Materiality remains low.

ACM Research, Inc. (Ticker: ACMR) � Deposito Form 144

Una persona di nome Lisa Yi Lu Feng ha presentato una comunicazione per la vendita di un massimo di 15.000 azioni ordinarie di ACM Research, Inc. tramite Morgan Stanley Smith Barney LLC. La data approssimativa della vendita è il 7 luglio 2025. In base alla comunicazione, le azioni sono valutate complessivamente a 420.000 $, rappresentando circa lo 0,023% delle 63.864.504 azioni in circolazione. Le azioni sono state acquisite lo stesso giorno mediante un esercizio di opzioni azionarie pagato in contanti.

La dichiarante ha inoltre rivelato una vendita precedente di 15.000 azioni avvenuta il 24 giugno 2025, che ha generato 390.000 $ di ricavi lordi.

  • Nel modulo non è stata specificata alcuna relazione con l’emittente e non sono state citate informazioni negative.
  • Il deposito indica conformità alla Regola 144 e possibile pianificazione secondo la regola 10b5-1, ma non è stata fornita la data di adozione del piano.

La transazione è di entità ridotta rispetto al numero totale di azioni ACMR, suggerendo un impatto limitato sull’offerta di azioni. Tuttavia, vendite ripetute da parte di insider in un breve arco di tempo potrebbero attirare l’attenzione degli investitori.

ACM Research, Inc. (Ticker: ACMR) � Presentación del Formulario 144

Una persona llamada Lisa Yi Lu Feng ha presentado un aviso para vender hasta 15,000 acciones comunes de ACM Research, Inc. a través de Morgan Stanley Smith Barney LLC. La fecha aproximada de venta es el 7 de julio de 2025. Según la presentación, las acciones tienen un valor agregado de $420,000, lo que representa aproximadamente el 0,023 % de las 63,864,504 acciones en circulación. Las acciones fueron adquiridas ese mismo día mediante un ejercicio de opciones sobre acciones pagado en efectivo.

El declarante también reveló una venta previa de 15,000 acciones el 24 de junio de 2025 que generó $390,000 en ingresos brutos.

  • No se especificó ninguna relación con el emisor en el formulario, ni se mencionó información adversa.
  • La presentación indica cumplimiento con la Regla 144 y posible planificación 10b5-1, pero no se proporcionó la fecha de adopción del plan.

La transacción es pequeña en relación con el número de acciones de ACMR, lo que sugiere un impacto limitado en la oferta de acciones. Sin embargo, ventas repetidas a nivel de insider en un corto período pueden llamar la atención de los inversores.

ACM Research, Inc. (티커: ACMR) � Form 144 제출

Lisa Yi Lu Feng라는 개인� Morgan Stanley Smith Barney LLC� 통해 ACM Research, Inc.� 15,000 보통�까지 매도� 예정임을 신고했습니다. 예상 매도일은 2025� 7� 7�입니�. 제출서에 따르�, 해당 주식� � 시장 가치는 � 420,000 달러�, 전체 발행 주식 63,864,504주의 � 0.023%� 해당합니�. � 주식은 같은 � 주식 옵션 행사� 통해 현금으로 취득되었습니�.

신고자는 또한 2025� 6� 24�15,000�� 매도하여 � 390,000 달러� 매출� 올린 사실� 공개했습니다.

  • 서식에는 발행사와� 관계가 명시되지 않았으며, 부정적� 정보� 없었습니�.
  • 신고� Rule 144 준� � 10b5-1 계획 가능성� 나타내지�, 계획 채택 날짜� 제공되지 않았습니�.

이번 거래� ACMR� � 주식 수에 비해 적은 규모�, 주식 공급� 미치� 영향은 제한적일 것으� 보입니다. 다만, 짧은 기간 � 반복적인 내부� 매도� 투자자들� 관심을 � � 있습니다.

ACM Research, Inc. (Symbole : ACMR) � Dépôt du formulaire 144

Une personne nommée Lisa Yi Lu Feng a déposé un avis pour vendre jusqu’� 15 000 actions ordinaires d’ACM Research, Inc. via Morgan Stanley Smith Barney LLC. La date approximative de la vente est le 7 juillet 2025. Selon le dépôt, les actions sont évaluées à un prix de marché total d’environ 420 000 $, ce qui représente environ 0,023 % des 63 864 504 actions en circulation. Les actions ont été acquises le même jour par l’exercice d�options d’achat d’actions payées en espèces.

Le déclarant a également révélé une vente antérieure de 15 000 actions le 24 juin 2025, générant 390 000 $ de produit brut.

  • Aucune relation avec l’émetteur n’a été spécifiée dans le formulaire, et aucune information défavorable n’a été mentionnée.
  • Le dépôt indique une conformité à la règle 144 et une planification possible selon la règle 10b5-1, mais aucune date d’adoption du plan n’est fournie.

La transaction est faible par rapport au nombre d’actions ACMR, suggérant un impact limité sur l’offre d’actions. Toutefois, des ventes répétées par des initiés sur une courte période pourraient attirer l’attention des investisseurs.

ACM Research, Inc. (Ticker: ACMR) � Form 144 Einreichung

Eine Person namens Lisa Yi Lu Feng hat eine Mitteilung eingereicht, um bis zu 15.000 Stammaktien von ACM Research, Inc. über Morgan Stanley Smith Barney LLC zu verkaufen. Das ungefähre Verkaufsdatum ist der 7. Juli 2025. Laut Einreichung haben die Aktien einen Gesamtmarktwert von 420.000 $ und entsprechen etwa 0,023 % der 63.864.504 ausstehenden Aktien. Die Aktien wurden am selben Tag durch die Ausübung von Aktienoptionen gegen Barzahlung erworben.

Der Einreicher gab außerdem einen vorherigen Verkauf von 15.000 Aktien am 24. Juni 2025 bekannt, der einen Bruttoerlös von 390.000 $ erzielte.

  • Im Formular wurde keine Beziehung zum Emittenten angegeben und keine negativen Informationen genannt.
  • Die Einreichung weist auf die Einhaltung von Regel 144 und mögliche 10b5-1-Planung hin, jedoch wurde kein Planannahmedatum angegeben.

Die Transaktion ist im Verhältnis zur Aktienanzahl von ACMR gering und dürfte die Aktienversorgung nur begrenzt beeinflussen. Wiederholte Insider-Verkäufe innerhalb kurzer Zeit könnten jedoch die Aufmerksamkeit der Investoren auf sich ziehen.


As filed with the Securities and Exchange Commission on July 7, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________

FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
______________________

SERVICENOW, INC.
(Exact name of registrant as specified in its charter)
Delaware20-2056195
(State or other jurisdiction
of incorporation or organization)
(I.R.S. Employer
Identification No.)
2225 Lawson Lane
Santa Clara, California 95054
(408) 501-8550
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
data.world, Inc. 2025 Restricted Stock Unit Plan1
(Full title of the plan)
______________________

William R. McDermott
Chairman and Chief Executive Officer
ServiceNow, Inc.
2225 Lawson Lane
Santa Clara, California 95054
(408) 501-8550
(Name, address, including zip code, and telephone number, including area code, of agent for service)
______________________

Please send copies of all communications to:
Kyle T. Seifried
Paul, Weiss, Rifkind, Wharton & Garrison LLP
1285 Avenue of the Americas
New York, New York 10019
(212) 373-3000
Russell S. Elmer
General Counsel and Secretary
ServiceNow, Inc.
2225 Lawson Lane
Santa Clara, California 95054
(408) 501-8550
______________________
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ý
Accelerated filer ¨
Non-accelerated filer ¨
Smaller reporting company ¨
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
____________
1 The Registrant assumed such plan and awards thereunder in connection with its acquisition of data.world, Inc.




SERVICENOW, INC.
REGISTRATION STATEMENT ON FORM S-8

This Registration Statement on Form S-8 is being filed by ServiceNow, Inc. (the “Registrant”) to register 21,205 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), pursuant to the Registrant’s assumption of the data.world, Inc. 2025 Restricted Stock Unit Plan (the “Plan”) and the outstanding, unvested restricted stock units thereunder. The Registrant assumed the Plan and such awards in connection with its acquisition of data.world, Inc.

PART I
Information Required in the Section 10(a) Prospectus

Information required by Part I of Form S-8 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”). The documents containing the information specified in Part I of Form S-8 will be sent or given to the participants in the Plan as specified by Rule 428(b)(1) under the Securities Act. Such documents need not be filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

PART II
Information Required in the Registration Statement
Item 3. Incorporation of Documents by Reference.
The Commission allows us to “incorporate by reference” into this Registration Statement certain information required to be included. This means that we can disclose important information to you by referring you to those documents where the information resides. The information we incorporate by reference is considered a part of this Registration Statement, and later information we file with the Commission will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings we make with the Commission under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on or after the date of this Registration Statement (other than information “furnished” under any current report or otherwise “furnished” to the Commission, and XBRL-related information, unless otherwise stated), and prior to the filing of a post-effective amendment to this Registration Statement that indicates all securities offered hereby have been sold or which deregisters all such securities then remaining unsold:

(a)the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on January 30, 2025;
(b)the information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K from our Definitive Proxy Statement on Schedule 14A filed with the Commission on April 4, 2025;

(c)the Registrant’s Current Reports on Form 8-K filed with the Commission on January 29, 2025, February 12, 2025, April 23, 2025, May 27, 2025 and May 30, 2025 (other than information “furnished” and not deemed to be “filed” in such Current Reports);

(d)the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on April 23, 2025; and

(e)the description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (Registration No. 001-35580) filed with the Commission on June 19, 2012 pursuant to Section 12(b) of the Exchange Act, as updated by Exhibit 4.5 to our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Commission on February 3, 2022, including any amendments or reports filed for the purpose of updating such description.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 4. Description of Securities.

Not applicable.




Item 5. Interests of Named Experts and Counsel.

Not applicable.

Item 6. Indemnification of Directors and Officers.

Section 145 of the Delaware General Corporation Law authorizes a court to award or a corporation’s board of directors to grant indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section 145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.

As permitted by the Delaware General Corporation Law, the Registrant’s restated certificate of incorporation includes a provision that eliminates, to the fullest extent permitted by law, the personal liability of a director for monetary damages resulting from breach of his or her fiduciary duty as a director, except for liability:

for any breach of the director’s duty of loyalty to the Registrant or its stockholders;

for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

under Section 174 of the Delaware General Corporation Law (regarding unlawful payments of dividends, stock repurchases or redemptions); or

for any transaction from which the director derived an improper personal benefit.

As permitted by the Delaware General Corporation Law, the Registrant’s restated bylaws provide that:

the Registrant is required to indemnify its directors and officers to the fullest extent permitted by the Delaware General Corporation Law, subject to certain very limited exceptions;

the Registrant may indemnify its other employees and agents as set forth in the Delaware General Corporation Law;

the Registrant is required to advance expenses, as incurred, to its directors and officers in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to certain very limited exceptions; and

the rights conferred in the Registrant’s restated bylaws are not exclusive.

In addition, the Registrant has entered into, and intends to continue to enter into, indemnification agreements with each of its current directors and executive officers. These agreements will provide for the indemnification of directors and executive officers for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were agents of the Registrant.

The Registrant currently carries liability insurance for its directors and officers for securities matters. The indemnification provisions in the Registrant’s restated certificate of incorporation, restated bylaws and the indemnification agreements entered into between the Registrant and each of its directors and executive officers are sufficiently broad to permit indemnification of the Registrant’s directors and executive officers for liabilities arising under the Securities Act.

See also the undertakings set out in response to Item 9 of this Registration Statement.

Item 7. Exemption from Registration Claimed.

Not applicable.




Item 8. Exhibits.

    The following is a complete list of exhibits filed as part of this Registration Statement:

ExhibitIncorporated by ReferenceFiled
NumberExhibit DescriptionFormFile No.ExhibitFiling DateHerewith
4.1
Restated Certificate of Incorporation of the Registrant, as amended, as currently in effect.
8-K001-355803.15/27/2025
4.2
Restated Bylaws of the Registrant, as amended, as currently in effect.
8-K001-355803.12/12/2025
4.3
Form of Common Stock Certificate.
S-1/A333-1804864.16/19/2012
4.4
data.world, Inc. 2025 Restricted Stock Unit Plan.
X
4.5
Form of Restricted Share Unit Award Agreement under data.world, Inc. 2025 Restricted Stock Unit Plan.
X
5.1
Opinion and Consent of Paul, Weiss, Rifkind, Wharton & Garrison LLP.
X
23.1
Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.
X
23.2
Consent of Paul, Weiss, Rifkind, Wharton & Garrison LLP (contained in Exhibit 5.1).
X
24.1
Power of Attorney (included on the signature page of this Registration Statement).
X
107
Filing Fee Table
X

Item 9. Undertakings.

1. The undersigned Registrant hereby undertakes:

(a) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

provided, however, that paragraphs (1)(a)(i) and (1)(a)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement;

(b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

(c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

2. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration.




Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereby, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.




SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Santa Clara, State of California, on this 7th day of July, 2025.
ServiceNow, Inc.
By:/s/ William R. McDermott
Name:William R. McDermott
Title:Chief Executive Officer




POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints William R. McDermott and Gina Mastantuono, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

SignatureTitleDate
/s/ William R. McDermott
Chairman and Chief Executive Officer
(Principal Executive Officer)
July 7, 2025
William R. McDermott
/s/ Gina Mastantuono
President and Chief Financial Officer
(Principal Financial Officer)
July 7, 2025
Gina Mastantuono
/s/ Kevin T. McBride
Chief Accounting Officer
(Principal Accounting Officer)
July 7, 2025
Kevin T. McBride
/s/ Frederic B. LuddyDirectorJuly 7, 2025
Frederic B. Luddy
/s/ Susan L. BostromDirectorJuly 7, 2025
Susan L. Bostrom
/s/ Teresa BriggsDirectorJuly 7, 2025
Teresa Briggs
/s/ Jonathan C. ChadwickDirectorJuly 7, 2025
Jonathan C. Chadwick
/s/ Paul E. ChamberlainDirectorJuly 7, 2025
Paul E. Chamberlain
/s/ Lawrence J. Jackson, Jr.DirectorJuly 7, 2025
Lawrence J. Jackson, Jr.
/s/ Joseph M. QuinlanDirectorJuly 7, 2025
Joseph M. Quinlan
/s/ Anita M. SandsDirectorJuly 7, 2025
Anita M. Sands

FAQ

How many ACMR shares are proposed for sale under this Form 144?

The filer intends to sell 15,000 common shares of ACM Research.

What is the estimated value of the ACM Research shares to be sold?

The filing cites an aggregate market value of $420,000 for the proposed sale.

When is the planned sale date for the ACMR shares?

The approximate sale date listed is 07 July 2025.

How many ACMR shares were sold by the same person in the past three months?

The filer previously sold 15,000 shares on 24 June 2025 for $390,000.

What percentage of ACMR’s outstanding shares does this sale represent?

About 0.023 % of ACM Research’s 63,864,504 shares outstanding.

Which broker will handle the ACMR share sale?

Morgan Stanley Smith Barney LLC is listed as the broker.
Servicenow Inc

NYSE:NOW

NOW Rankings

NOW Latest News

NOW Latest SEC Filings

NOW Stock Data

199.36B
206.72M
0.18%
92.51%
1.62%
Software - Application
Services-prepackaged Software
United States
SANTA CLARA